Reuters logo
BRIEF-Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti
October 23, 2017 / 11:43 AM / a month ago

BRIEF-Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti

Oct 23 (Reuters) - Evoke Pharma Inc:

* Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™

* Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018​

* Evoke Pharma Inc- ‍relative to safety, all gimoti doses were well-tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below